Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study
Martin Dreyling(LMU Klinikum), Wojciech Jurczak(Jagiellonian University), Mats Jerkeman(Skåne University Hospital), Rodrigo Santucci Silva(Faculdade São Lucas), Chiara Rusconi(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Marek Trněný(Ocní klinika), Fritz Offner(Ghent University Hospital), Dolores Caballero(Instituto de Investigación Biomédica de Salamanca), Cristina João(Champalimaud Foundation), Mathias Witzens‐Harig(Heidelberg University), Georg Heß(Johannes Gutenberg University Mainz), Isabelle Bence‐Bruckler(Ottawa Hospital), Seok‐Goo Cho(The Catholic University of Korea Seoul St. Mary's Hospital), John Bothos(Janssen (United States)), Jenna D Goldberg(Janssen (United States)), Christopher Enny(Janssen (United States)), Shana Traina(Janssen (United States)), Sriram Balasubramanian(Janssen (United States)), Nibedita Bandyopadhyay(Janssen (United States)), Steven Sun(Janssen (United States)), Jessica Vermeulen(Janssen (Netherlands)), Aleksandra Rizo(Janssen (United States)), Simon Rule(Derriford Hospital)
Cited by 461Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis